Respected Florida based US research house Redchip, has re-rated ASX listed cancer drug hopeful Pharm, page-17

Bow ties, xylophones and patsy questions for sure, not to mention implausibly good looking lab workers, but if it works, well and good.

That Redchip's objectivity is in doubt is undeniable but neither is it unprecedented or disguised.

The comparison of market cap with similar stage ventures points, at the very least, to some relative undervaluation.
The extent of that undervaluation is, of course, highly subjective but something's caught the market's attention.

What might also be behind both share price and volume rises is the 8th March announcement that
a leading UK-based clinical oncologist is to evaluate monepantel in patients with oesophageal cancer and that " Similar studies will be undertaken with patients suffering with two other types of cancer at two different centres in Australia and the US respectively."

Expansion out of Australia is something PAA has been aspiring to for some time and will add to both the credibility and marketability of the phase 2 trials outcomes.

In short there's likely to be more to the recent interest in PAA than Redchip's stylised puffery alone.